Compare EchoStar Corporation Common Stock (ECHO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EchoStar Corporation Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? EchoStar Corporation Common Stock trades at $87.35 (market cap $26.63B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: EchoStar Corporation Common Stock is far larger — about 27.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, EchoStar Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ECHO | MRVI | |
|---|---|---|
Market Cap | $26.63B | $972.90M |
Volume | 2,918,300 | 4,325,710 |
Sector | Media | Health |
52-Week High | $141.80 | $9.00 |
52-Week Low | $66.93 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $43.68B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECHO trades at $91.56, down 3.72% over 24 hours, with a neutral technical signal and mixed earnings history including a significant Q2 2026 beat. The company reported a net loss of $14.50 billion in 2025, with negative cash flows, though revenue remains substantial at $15.00 billion. Recent news highlights institutional investments and a strategic partnership with United Airlines for in-flight streaming.
Analyst consensus is strongly bullish with a $134.00 price target, but high risks stem from persistent losses, negative cash flow, and the Hughes unit's bankruptcy. The stock's appeal hinges on turnaround execution and debt reduction efforts outweighing fundamental weaknesses.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EchoStar Corporation Common Stock
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
